Chardan Capital Reiterates Buy Rating on CAMP4 Therapeutics
Chardan Capital maintains its buy rating on CAMP4 Therapeutics, setting a target price of $6.50.
Key Points
- Chardan Capital reiterated its buy rating for CAMP4 Therapeutics with a target price of $6.50, as of June 10, 2026.
- CAMP4 Therapeutics trades near $4.19 with a market cap of about $217.6 million, and a 52-week high of $7.75.
- Insiders including Douglas Williams and Andrew Schwab bought 28,000 shares each on June 10, 2026.
Chardan Capital has reiterated its buy rating on CAMP4 Therapeutics Corporation (NasdaqGM: CAMP) with a price target of $6.50. This update came on June 10, 2026, as the stock traded around $4.19.
Other Institutional Activity in CAMP4 Therapeutics
Janus Henderson Group maintained its position with 6,307,636 shares valued at about $27.88 million. Similarly, 5AM Venture Management held steady at 5,869,091 shares worth approximately $25.88 million. FMR LLC increased its holdings by 15,189 shares, bringing its total to 4,933,432 shares valued at $21.76 million. Balyasny Asset Management added 195,537 shares, reaching a total of 2,632,437 shares worth around $11.61 million. In contrast, Enavate Sciences GP reduced its position by 844,905 shares, now holding 2,190,920 shares valued at about $9.66 million.
CAMP4 Therapeutics Stock Snapshot
Shares of CAMP4 Therapeutics are currently trading near $4.19. The company has a market cap of approximately $217.6 million. It is not profitable yet, so it doesn't have a meaningful P/E ratio. The stock's 52-week range is between $1.31 and $7.75, with a 50-day moving average of $4.34 and a 200-day moving average of $4.20. CAMP4 maintains a strong current ratio of 6.15 and a quick ratio of 5.97, though it has a high debt-to-equity ratio of 6.87.
Insider Buying and Selling at CAMP4 THERAPEUTICS CORPORATION
On June 10, 2026, several insiders made significant purchases of CAMP4 stock. Douglas Williams, Andrew Schwab, Steven Holtzman, Amir Nashat, Richard Young, and Murray Stewart each bought 28,000 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 10, 2026, Chardan Capital reiterated its buy rating and set a price target of $6.50 for CAMP4 Therapeutics. Other analysts have also shown confidence in the stock. Rodman & Renshaw initiated coverage with a buy rating and a $7.00 target on April 14, 2026. Leerink Partners maintained its buy rating with a $9.00 target on April 2, 2026. The consensus among analysts is a strong buy, with a mean target price of $7.92 based on six opinions.
About CAMP4 Therapeutics
CAMP4 Therapeutics Corporation is a biotech firm based in Cambridge, Massachusetts. It focuses on discovering and developing RNA-based therapies for genetic diseases. Its lead candidate, CMP-001, is undergoing clinical trials for urea cycle disorders. The company also works on CMP-002 for SYNGAP1-related disorders. Founded in 2015, CAMP4 is led by CEO Joshua Mandel-Brehm and employs 48 people.
Bottom Line
Chardan Capital's reiterated buy rating reflects optimism about CAMP4 Therapeutics' potential. Investors track such ratings closely, although it's important to remember that analyst opinions are just one piece of the puzzle. The backward-looking nature of these reports means they may not reflect the current state of affairs, but they can provide insight into market sentiment.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.